IMUNON Highlights Phase 2 Data on IMNN-001 for Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a pioneering clinical-stage biotechnology company, is set to present new clinical data from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for advanced ovarian cancer. This presentation will take place at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, a noteworthy event in the scientific community dedicated to cancer research.
Key Highlights from the OVATION 2 Study
During this phase of the study, IMUNON has gathered compelling evidence showcasing the efficacy of IMNN-001 in improving patient outcomes. The median overall survival rates of patients treated with IMNN-001 exhibited a remarkable 11.1-month increase compared to those receiving the standard care. This represents a significant 35% improvement in survival rates, marking a pivotal moment in the fight against ovarian cancer.
What This Means for Patients
The implications of these results are profound. For women diagnosed with advanced ovarian cancer, the potential of IMNN-001 to enhance survival rates signifies hope for patients facing this challenging diagnosis. By potentially increasing overall survival, IMUNON aims to change the landscape of treatment options available. Dr. Stacy Lindborg, CEO of IMUNON, expressed optimism about the upcoming presentation and the promising data generated so far.
FDA Collaboration and Next Steps
In addition to the presentation, IMUNON will meet with the U.S. Food and Drug Administration (FDA) to discuss the Phase 3 trial design for IMNN-001, with expectations for this pivotal study to commence in the first quarter of 2025. Such interactions indicate the FDA's vested interest in this innovative therapy, especially as they take place in person, something less common in recent times.
Overview of the Study's Details
Scheduled for November 8, the SITC poster presentation will feature the abstract titled 'Phase I/II study of Safety and Efficacy of Intraperitoneal IMNN-001 with Neoadjuvant Chemotherapy of Paclitaxel and Carboplatin in Patients Newly Diagnosed with Advanced Epithelial Ovarian Cancer.' This presentation will be given by Dr. Jennifer Scalici, a reputable adjunct professor from Emory University, who will discuss the safety and efficacy findings from the ongoing study.
About IMUNON and Its Innovative Approaches
IMUNON has positioned itself as a leader in biotechnology, focusing on harnessing the body’s own mechanisms to develop treatments that are not only effective but also safe and long-lasting. Their proprietary TheraPlas® technology enables DNA-mediated delivery systems that enhance immune response, showcasing a novel approach to combating cancer and other diseases.
The innovative platform allows IL-12 DNA plasmid vectors to be delivered effectively with nanoparticles, ensuring targeted action and sustained production of cancer-fighting proteins within the body. IMNN-001 exemplifies this technology, aiming specifically at treating advanced ovarian cancer by enabling the body to generate robust immune responses against tumor cells.
Future Directions for IMUNON
Moving forward, IMUNON remains steadfast in its commitment to clinical development and research endeavors. The company is also progressing in trials for its COVID-19 booster vaccine, IMNN-101, further underlining its dedication to addressing urgent medical needs.
Frequently Asked Questions
What is IMNN-001?
IMNN-001 is an investigational DNA-mediated immunotherapy designed to treat advanced ovarian cancer, showcasing positive results in Phase 2 trials.
When will the Phase 3 trial of IMNN-001 begin?
The Phase 3 pivotal trial for IMNN-001 is expected to start in the first quarter of 2025.
What are the key results from the OVATION 2 Study?
The OVATION 2 Study reported an 11.1-month increase in median overall survival for patients treated with IMNN-001 compared to standard care.
Who is presenting the findings at the SITC meeting?
Dr. Jennifer Scalici will be presenting the findings as part of the SITC poster presentation for the OVATION 2 Study.
What is the TheraPlas® platform technology?
TheraPlas® is IMUNON's proprietary technology that enables effective delivery of DNA therapeutics, fostering strong immune responses against cancer.
